SurModics Net Worth
SurModics Net Worth Breakdown | SRDX |
SurModics Net Worth Analysis
SurModics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including SurModics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of SurModics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform SurModics' net worth analysis. One common approach is to calculate SurModics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares SurModics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing SurModics' net worth. This approach calculates the present value of SurModics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of SurModics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate SurModics' net worth. This involves comparing SurModics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into SurModics' net worth relative to its peers.
Enterprise Value |
|
To determine if SurModics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding SurModics' net worth research are outlined below:
| SurModics is way too risky over 90 days horizon | |
| SurModics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 132.58 M. Net Loss for the year was (1.54 M) with profit before overhead, payroll, taxes, and interest of 29 M. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Why Is Perrigo Down 15.1 percent Since Last Earnings Report |
SurModics Quarterly Good Will |
|
SurModics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in SurModics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to SurModics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
SurModics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SurModics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. SurModics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Hold |
Most SurModics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand SurModics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of SurModics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSurModics Target Price Projection
SurModics' current and average target prices are 41.91 and 59.50, respectively. The current price of SurModics is the price at which SurModics is currently trading. On the other hand, SurModics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On SurModics Target Price
Know SurModics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as SurModics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading SurModics backward and forwards among themselves. SurModics' institutional investor refers to the entity that pools money to purchase SurModics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-03-31 | 383.7 K | Bank Of America Corp | 2024-03-31 | 320.4 K | Geode Capital Management, Llc | 2024-03-31 | 308.1 K | State Street Corporation | 2024-03-31 | 302.1 K | Kennedy Capital Management Inc | 2024-03-31 | 138.4 K | Northern Trust Corp | 2024-03-31 | 132.8 K | Jacobs Levy Equity Management, Inc. | 2024-03-31 | 121.8 K | Salem Investment Counselors Inc | 2024-03-31 | 121 K | Charles Schwab Investment Management Inc | 2024-03-31 | 111.6 K | Trigran Investments Inc | 2024-03-31 | 2.4 M | Blackrock Inc | 2024-03-31 | 1.1 M |
Follow SurModics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 598.27 M.Market Cap |
|
Project SurModics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.02) | (0.01) | |
| Return On Capital Employed | 0.04 | 0.03 | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
When accessing SurModics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures SurModics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of SurModics' profitability and make more informed investment decisions.
The data published in SurModics' official financial statements typically reflect SurModics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving SurModics' quantitative information. For example, before you start analyzing numbers published by SurModics accountants, it’s essential to understand SurModics' liquidity, profitability, and earnings quality within the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the imprecision that can be found in SurModics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SurModics. Check SurModics' Beneish M Score to see the likelihood of SurModics' management manipulating its earnings.
Evaluate SurModics' management efficiency
SurModics has return on total asset (ROA) of 0.0661 % which means that it generated a profit of $0.0661 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1192 %, meaning that it created $0.1192 on every $100 dollars invested by stockholders. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.01 in 2024. Return On Capital Employed is likely to drop to 0.03 in 2024. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2024, whereas Total Assets are likely to drop slightly above 140.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.69 | 5.39 | |
| Tangible Book Value Per Share | 3.26 | 4.03 | |
| Enterprise Value Over EBITDA | 27.06 | 43.46 | |
| Price Book Value Ratio | 4.32 | 5.69 | |
| Enterprise Value Multiple | 27.06 | 43.46 | |
| Price Fair Value | 4.32 | 5.69 | |
| Enterprise Value | 394.4 M | 410.8 M |
The analysis of SurModics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze SurModics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of SurModics Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 2.7667 | Revenue 143 M | Quarterly Revenue Growth 0.175 | Revenue Per Share 10.147 | Return On Equity 0.1192 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SurModics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SurModics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SurModics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gary Maharaj over three weeks ago Acquisition by Gary Maharaj of 24356 shares of SurModics subject to Rule 16b-3 | ||
Susan Knight over a month ago Acquisition by Susan Knight of 1944 shares of SurModics subject to Rule 16b-3 | ||
Jose Bedoya over a month ago Disposition of 32 shares by Jose Bedoya of SurModics at 23.95 subject to Rule 16b-3 | ||
Joseph Stich over six months ago Payment of 908 shares by Joseph Stich of SurModics subject to Rule 16b-3 | ||
Joseph Stich over six months ago Acquisition by Joseph Stich of 6302 shares of SurModics subject to Rule 16b-3 | ||
Joseph Stich over six months ago Payment of 701 shares by Joseph Stich of SurModics subject to Rule 16b-3 | ||
Joseph Stich over six months ago Exercise or conversion by Joseph Stich of 17121 shares of SurModics subject to Rule 16b-3 |
SurModics Corporate Filings
13A | 10th of June 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 29th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify | |
13A | 13th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
SurModics Earnings Estimation Breakdown
The calculation of SurModics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of SurModics is estimated to be -0.33 with the future projection ranging from a low of -0.38 to a high of -0.3. Please be aware that this consensus of annual earnings estimates for SurModics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.38 Lowest | Expected EPS | -0.3 Highest |
SurModics Earnings Projection Consensus
Suppose the current estimates of SurModics' value are higher than the current market price of the SurModics stock. In this case, investors may conclude that SurModics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and SurModics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2024 | Current EPS (TTM) | |
| 4 | 50.14% | 0.07 | -0.33 | 0.96 |
SurModics Earnings History
Earnings estimate consensus by SurModics analysts from Wall Street is used by the market to judge SurModics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only SurModics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.SurModics Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of SurModics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
SurModics Earnings per Share Projection vs Actual
Actual Earning per Share of SurModics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering SurModics predict the company's earnings will be in the future. The higher the earnings per share of SurModics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.SurModics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as SurModics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of SurModics should always be considered in relation to other companies to make a more educated investment decision.SurModics Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact SurModics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-01 | 2024-03-31 | -0.32 | 0.07 | 0.39 | 121 | ||
2024-02-01 | 2023-12-31 | -0.3 | -0.06 | 0.24 | 80 | ||
2023-11-08 | 2023-09-30 | 0.19 | 0.53 | 0.34 | 178 | ||
2023-08-02 | 2023-06-30 | 0.05 | 0.52 | 0.47 | 940 | ||
2023-04-26 | 2023-03-31 | -0.51 | -0.4 | 0.11 | 21 | ||
2023-02-06 | 2022-12-31 | -0.66 | -0.5 | 0.16 | 24 | ||
2022-11-09 | 2022-09-30 | -0.45 | -0.26 | 0.19 | 42 | ||
2022-07-27 | 2022-06-30 | -0.38 | -0.34 | 0.04 | 10 | ||
2022-04-27 | 2022-03-31 | -0.34 | -0.22 | 0.12 | 35 | ||
2022-02-03 | 2021-12-31 | -0.31 | -0.13 | 0.18 | 58 | ||
2021-11-10 | 2021-09-30 | -0.25 | -0.1 | 0.15 | 60 | ||
2021-08-04 | 2021-06-30 | -0.17 | -0.17 | 0.0 | 0 | ||
2021-04-28 | 2021-03-31 | 0.63 | 0.62 | -0.01 | 1 | ||
2021-02-09 | 2020-12-31 | -0.09 | 0.02 | 0.11 | 122 | ||
2020-11-04 | 2020-09-30 | -0.08 | -0.18 | -0.1 | 125 | ||
2020-08-05 | 2020-06-30 | 0.19 | 0.21 | 0.02 | 10 | ||
2020-04-29 | 2020-03-31 | -0.11 | 0.04 | 0.15 | 136 | ||
2020-02-05 | 2019-12-31 | -0.08 | 0.05 | 0.13 | 162 | ||
2019-10-31 | 2019-09-30 | 0.37 | 0.37 | 0.0 | 0 | ||
2019-07-31 | 2019-06-30 | 0.05 | 0.15 | 0.1 | 200 | ||
2019-05-01 | 2019-03-31 | -0.02 | 0.07 | 0.09 | 450 | ||
2019-01-30 | 2018-12-31 | -0.03 | 0.12 | 0.15 | 500 | ||
2018-11-09 | 2018-09-30 | -0.03 | 0.05 | 0.08 | 266 | ||
2018-08-06 | 2018-06-30 | -0.24 | 0.27 | 0.51 | 212 | ||
2018-05-02 | 2018-03-31 | -0.08 | 0.07 | 0.15 | 187 | ||
2018-02-08 | 2017-12-31 | -0.1 | 0.1 | 0.2 | 200 | ||
2017-11-08 | 2017-09-30 | -0.01 | 0.18 | 0.19 | 1900 | ||
2017-08-03 | 2017-06-30 | -0.02 | 0.09 | 0.11 | 550 | ||
2017-04-27 | 2017-03-31 | 0.07 | 0.05 | -0.02 | 28 | ||
2017-02-02 | 2016-12-31 | 0.09 | 0.19 | 0.1 | 111 | ||
2016-11-16 | 2016-09-30 | 0.09 | 0.26 | 0.17 | 188 | ||
2016-07-28 | 2016-06-30 | 0.12 | 0.37 | 0.25 | 208 | ||
2016-05-02 | 2016-03-31 | 0.09 | 0.2 | 0.11 | 122 | ||
2016-01-28 | 2015-12-31 | 0.17 | 0.38 | 0.21 | 123 | ||
2015-11-10 | 2015-09-30 | 0.19 | 0.3 | 0.11 | 57 | ||
2015-08-05 | 2015-06-30 | 0.21 | 0.26 | 0.05 | 23 | ||
2015-04-30 | 2015-03-31 | 0.2 | 0.19 | -0.01 | 5 | ||
2015-01-29 | 2014-12-31 | 0.21 | 0.25 | 0.04 | 19 | ||
2014-11-06 | 2014-09-30 | 0.25 | 0.26 | 0.01 | 4 | ||
2014-07-31 | 2014-06-30 | 0.23 | 0.27 | 0.04 | 17 | ||
2014-05-01 | 2014-03-31 | 0.2 | 0.22 | 0.02 | 10 | ||
2014-01-30 | 2013-12-31 | 0.21 | 0.21 | 0.0 | 0 | ||
2013-11-05 | 2013-09-30 | 0.22 | 0.26 | 0.04 | 18 | ||
2013-07-31 | 2013-06-30 | 0.21 | 0.21 | 0.0 | 0 | ||
2013-05-07 | 2013-03-31 | 0.21 | 0.25 | 0.04 | 19 | ||
2013-01-30 | 2012-12-31 | 0.18 | 0.22 | 0.04 | 22 | ||
2012-11-06 | 2012-09-30 | 0.17 | 0.17 | 0.0 | 0 | ||
2012-08-01 | 2012-06-30 | 0.13 | 0.17 | 0.04 | 30 | ||
2012-05-08 | 2012-03-31 | 0.12 | 0.14 | 0.02 | 16 | ||
2012-02-02 | 2011-12-31 | 0.11 | 0.11 | 0.0 | 0 | ||
2011-11-03 | 2011-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2011-08-03 | 2011-06-30 | 0.04 | 0.13 | 0.09 | 225 | ||
2010-11-10 | 2010-09-30 | 0.13 | -1.2469 | -1.3769 | 1059 | ||
2010-07-28 | 2010-06-30 | 0.14 | -0.05 | -0.19 | 135 | ||
2010-04-28 | 2010-03-31 | 0.17 | 0.1 | -0.07 | 41 | ||
2010-01-27 | 2009-12-31 | 0.17 | 0.11 | -0.06 | 35 | ||
2009-11-04 | 2009-09-30 | 0.2 | 0.16 | -0.04 | 20 | ||
2009-07-29 | 2009-06-30 | 0.2 | 0.2 | 0.0 | 0 | ||
2009-04-29 | 2009-03-31 | 0.19 | 0.24 | 0.05 | 26 | ||
2009-01-28 | 2008-12-31 | 0.26 | 0.16 | -0.1 | 38 | ||
2008-11-05 | 2008-09-30 | 0.28 | -0.05 | -0.33 | 117 | ||
2008-07-23 | 2008-06-30 | 0.31 | 0.26 | -0.05 | 16 | ||
2008-04-23 | 2008-03-31 | 0.3 | 0.28 | -0.02 | 6 | ||
2008-01-23 | 2007-12-31 | 0.31 | 0.31 | 0.0 | 0 | ||
2007-11-06 | 2007-09-30 | 0.36 | 0.09 | -0.27 | 75 | ||
2007-07-18 | 2007-06-30 | 0.36 | 0.31 | -0.05 | 13 | ||
2007-04-18 | 2007-03-31 | 0.34 | 0.31 | -0.03 | 8 | ||
2007-01-24 | 2006-12-31 | 0.34 | 0.32 | -0.02 | 5 | ||
2006-11-01 | 2006-09-30 | 0.34 | 0.34 | 0.0 | 0 | ||
2006-07-19 | 2006-06-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2006-04-19 | 2006-03-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2006-01-25 | 2005-12-31 | 0.31 | 0.35 | 0.04 | 12 | ||
2005-10-26 | 2005-09-30 | 0.32 | 0.33 | 0.01 | 3 | ||
2005-07-20 | 2005-06-30 | 0.3 | 0.32 | 0.02 | 6 | ||
2005-04-20 | 2005-03-31 | 0.27 | 0.32 | 0.05 | 18 | ||
2005-01-26 | 2004-12-31 | 0.25 | 0.32 | 0.07 | 28 | ||
2004-10-27 | 2004-09-30 | 0.21 | 0.31 | 0.1 | 47 | ||
2004-07-21 | 2004-06-30 | 0.19 | 0.22 | 0.03 | 15 | ||
2004-04-21 | 2004-03-31 | 0.25 | 0.25 | 0.0 | 0 | ||
2004-01-21 | 2003-12-31 | 0.3 | 0.23 | -0.07 | 23 | ||
2003-10-29 | 2003-09-30 | 0.24 | 0.25 | 0.01 | 4 | ||
2003-07-17 | 2003-06-30 | 0.13 | 0.26 | 0.13 | 100 | ||
2003-04-16 | 2003-03-31 | 0.13 | 0.15 | 0.02 | 15 | ||
2003-01-16 | 2002-12-31 | 0.1 | 0.12 | 0.02 | 20 | ||
2002-10-24 | 2002-09-30 | 0.13 | 0.15 | 0.02 | 15 | ||
2002-07-16 | 2002-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2002-04-16 | 2002-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2002-01-15 | 2001-12-31 | 0.08 | 0.08 | 0.0 | 0 | ||
2001-10-25 | 2001-09-30 | 0.12 | 0.12 | 0.0 | 0 | ||
2001-07-17 | 2001-06-30 | 0.09 | 0.09 | 0.0 | 0 | ||
2001-04-17 | 2001-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2001-01-16 | 2000-12-31 | 0.06 | 0.08 | 0.02 | 33 | ||
2000-10-26 | 2000-09-30 | 0.07 | 0.05 | -0.02 | 28 | ||
2000-07-18 | 2000-06-30 | 0.04 | 0.05 | 0.01 | 25 | ||
2000-04-18 | 2000-03-31 | 0.05 | 0.06 | 0.01 | 20 | ||
2000-01-18 | 1999-12-31 | 0.04 | 0.06 | 0.02 | 50 | ||
1999-10-29 | 1999-09-30 | 0.03 | 0.07 | 0.04 | 133 | ||
1999-07-20 | 1999-06-30 | 0.06 | 0.08 | 0.02 | 33 | ||
1999-04-20 | 1999-03-31 | 0.07 | 0.07 | 0.0 | 0 | ||
1999-01-19 | 1998-12-31 | 0.05 | 0.06 | 0.01 | 20 | ||
1998-11-05 | 1998-09-30 | 0.03 | 0.04 | 0.01 | 33 | ||
1998-07-21 | 1998-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
1998-04-23 | 1998-03-31 | 0.02 | 0.03 | 0.01 | 50 |
SurModics Corporate Management
| Charles Olson | Sr. VP and General Manager of Medical Device | Profile | |
| Timothy Arens | VP of Corporate Devel. and Strategy | Profile | |
| Joseph Stich | VP and General Manager of In-Vitro Diagnostics | Profile | |
| Gordon Weber | General Legal | Profile | |
| Teryl Sides | Senior Interventions | Profile | |
| John Manders | Corporate Controller and Principal Accounting Officer | Profile |
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.